Latest news with #VG-3927
Business Upturn
24-05-2025
- Business
- Business Upturn
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGMA, VIGL, STRR on Behalf of Shareholders
NEW YORK, May 24, 2025 (GLOBE NEWSWIRE) — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: SigmaTron International, Inc. (NASDAQ: SGMA)'s sale to Transom Capital Group, LLC for $3.02 per share in cash. If you are a SigmaTron shareholder, click here to learn more about your rights and options. Vigil Neuroscience, Inc. (NASDAQ: VIGL)'s sale to Sanofi. Under the terms of the proposed transaction, Vigil shareholders will receive $8.00 per share in cash and a non-tradeable contingent value right entitling shareholders to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. If you are a Vigil shareholder, click here to learn more about your legal rights and options. Star Equity Holdings, Inc. (NASDAQ: STRR)'s sale to Hudson Global, Inc. Upon completion of the proposed transaction, Star shareholders will own approximately 21% of the combined company. If you are a Star shareholder, click here to learn more about your legal rights and options. Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected]. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information:Halper Sadeh LLCDaniel Sadeh, Halper, World Trade Center85th FloorNew York, NY 10007(212) 763-0060 [email protected] [email protected]
Yahoo
23-05-2025
- Business
- Yahoo
Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi
Vigil Neuroscience shares more than tripled Thursday after the company reached a deal to be acquired by Sanofi. French pharmaceutical giant Sanofi agreed to pay $8.00 per share in cash at closing, or $470 million, plus $2.00 more per share in cash if Vigil's Alzheimer's drug achieves commercial sales. Vigil's drug VG-3927 is a Phase 2-ready clinical candidate, it Neuroscience (VIGL) shares jumped nearly 250% Thursday after the Alzheimer's disease drug developer reached a deal to be acquired by French pharmaceutical giant Sanofi (SNY). Sanofi agreed to pay $8.00 per share in cash at closing, a significant premium over Vigil's closing price of $2.31 on Wednesday, for a total of $470 million. The company will pay an additional $2.00 per share in cash if Vigil's Alzheimer's drug, VG-3927, achieves commercial sales, which would bring the total to $600 million. The deal is expected to close in the third quarter of 2025. VG-3927 is a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease, Vigil said. U.S.-listed shares of Sanofi edged lower in recent trading Thursday. The stock is up nearly 10% in 2025 so far. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
Vigil Neuroscience to be acquired by Sanofi for $8.00 per share
Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which Sanofi will acquire Vigil for an upfront payment of $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the transaction, including the potential CVR payment, represents approximately $600 million on a fully diluted basis. 'We are incredibly proud of the legacy we have built at Vigil and today's announcement is a testament to the value of our TREM2 agonist pipeline,' said Ivana Magovevi-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. 'Sanofi's development capabilities, therapeutic expertise, global footprint, and financial strength provide the greatest opportunity to further the development of VG-3927 for the potential treatment of Alzheimer's disease and potentially bring this important and differentiated therapy to those struggling with the immense burden of this disease.' Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on VIGL: Disclaimer & DisclosureReport an Issue Vigil Neuroscience Inc trading halted, news pending Vigil Neuroscience Advances Clinical Trials and Financial Stability Vigil Neuroscience reports Q1 EPS (49c) vs. (50c) last year Vigil Neuroscience sees cash runway into 2026 Vigil presents data on oral small molecule program including VG-3927 Sign in to access your portfolio
Business Wire
22-05-2025
- Business
- Business Wire
VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Vigil Neuroscience, Inc. (NasdaqGS: VIGL) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Vigil will receive $8.00 in cash for each share of Vigil that they own as well as a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash (payable following the first commercial sale of VG-3927 if achieved within a specific period). KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
22-05-2025
- Business
- Business Wire
Shareholder Alert: The Ademi Firm Investigates Whether Vigil Neuroscience Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Vigil (Nasdaq: VIGL) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Vigil will receive $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the transaction, including the potential CVR payment, represents approximately $600 million on a fully diluted basis. Vigil insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Vigil by imposing a significant penalty if Vigil accepts a competing bid. We are investigating the conduct of the Vigil board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
